Business
Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting
Shareholders approve 29th consecutive dividend increase to CHF 3.70 (+5.7%) per share for 2025, representing a 3.0% yield¹Shareholders confirm Giovanni Caforio as Chair of the Board of Directors as well as all other members of the Board of Directors who stood for re-election; Charles Swanton newly elected as member of the Board of DirectorsShareholders approve all other proposals by the Board of Directors, including the reduction of share capital, the 2025 report on nonfinancial matters and the
About this update from Novartis Ag
[{"type":"image","alt":"Novartis Pharma AG","displaySize":"","headline":null,"caption":"Novartis Pharma AG","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":104,"url":"https://media.zenfs.com/en/globenewswire.com/3c597efe92519a4a8a646c2639fa7252"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/6KjMGJHKhj2fey6YfY3waA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0NjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3c597efe92519a4a8a646c2639fa7252","width":300,"height":104}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Shareholders approve 29th consecutive dividend increase to CHF 3.70 (+5.7%) per share for 2025, representing a 3.0% yield¹","length":122,"tagName":"p"}]},{"val":[{"type":"text","content":"Shareholders confirm Giovanni Caforio as Chair of the Board of Directors as well as all other members of the Board of Directors who stood for re-election; Charles Swanton newly elected as member of the Board of Directors","length":220,"tagName":"p"}]},{"val":[{"type":"text","content":"Shareholders approve all other proposals by the Board of Directors, including the reduction of share capital, the 2025 report on nonfinancial matters and the 2025 Compensation Report, as well as the future Board and Executive Committee compensation in separate binding votes","length":274,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":616,"olType":false},{"type":"text","content":"Basel, March 6, 2026 – Novartis shareholders today agreed to the Board of Directors’ recommendations for all proposed resolutions at the company’s Annual General Meeting (AGM). A total of 1 554 shareholders were present at the meeting held in Basel, representing approximately 59.15% of the issued shares of Novartis. With a dividend increase of 5.7% to CHF 3.70 per share, shareholders approved the 29th consecutive increase, resulting in a dividend yield of 3.0%¹. Payment of the 2025 dividend will be made from March 12, 2026. Election of a new member of the Board of DirectorsShareholders have re-elected Giovanni Caforio as member of the Board of Directors and Board Chair. In addition, shareholders elected Charles Swanton as new member of the Board of Directors. Daniel Hochstrasser did not stand for re-election. All other members of the Board of Directors have been re-elected. All elections and re-elections pertain to a term las...